26 results on '"Fornasiero, Arianna"'
Search Results
2. Analysis of coding and non-coding transcriptome of peripheral B cells reveals an altered interferon response factor (IRF)-1 pathway in multiple sclerosis patients
3. Bacille Calmette-Guérin (BCG) Vaccine in Neuroinflammation
4. Contributors
5. Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study
6. Contributors
7. Chemical Elements and Oxidative Status in Neuroinflammation
8. Intestinal Permeability and Circulating CD161+CCR6+CD8+T Cells in Patients With Relapsing–Remitting Multiple Sclerosis Treated With Dimethylfumarate
9. Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study
10. Chapter 3 - Bacille Calmette-Guérin (BCG) Vaccine in Neuroinflammation
11. Autoimmune Encephalitis and CSF Anti-GluR3 Antibodies in an MS Patient after Alemtuzumab Treatment
12. The Contribution of Gut Barrier Changes to Multiple Sclerosis Pathophysiology
13. Drug Holiday of Interferon Beta 1b in Multiple Sclerosis: A Pilot, Randomized, Single Blind Study of Non-inferiority
14. Genome-Wide Multiple Sclerosis Association Data and Coagulation
15. Chapter 5 - Chemical Elements and Oxidative Status in Neuroinflammation
16. Fingolimod vs dimethyl fumarate in multiple sclerosis
17. Corrigendum to “Novel homozygous GBA2 mutation in a patient with complicated spastic paraplegia” [Clin. Neurol. Neurosurg. 168 (May) (2018) 60–63]
18. Novel homozygous GBA2 mutation in a patient with complicated spastic paraplegia
19. Leptomeningitis in a Person with Radiologically Isolated Syndrome and Latent Tuberculosis: A Case Report with Implications for Clinical Research
20. Rhizome
21. Altered intestinal permeability in patients with relapsing–remitting multiple sclerosis: A pilot study
22. IFN-β Therapy Regulates TLR7-Mediated Response in Plasmacytoid Dendritic Cells of Multiple Sclerosis Patients Influencing an Anti-Inflammatory Status
23. Altered intestinal permeability in patients with relapsing–remitting multiple sclerosis: A pilot study.
24. Epstein-Barr virus genetic variants are associated with multiple sclerosis.
25. Italian Alemtuzumab Study Group. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study
26. Altered intestinal permeability in patients with relapsing-remitting multiple sclerosis: A pilot study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.